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Abstract
Background: Regulatory T lymphocytes (Treg) infiltrate human glioblastoma (GBM); are involved in tumor progression and
correlate with tumor grade. Transient elimination of Tregs using CD25 depleting antibodies (PC61) has been found to
mediate GBM regression in preclinical models of brain tumors. Clinical trials that combine Treg depletion with tumor
vaccination are underway to determine whether transient Treg depletion can enhance anti-tumor immune responses and
improve long term survival in cancer patients.
Findings: Using a syngeneic intracrabial glioblastoma (GBM) mouse model we show that systemic depletion of Tregs 15
days after tumor implantation using PC61 resulted in a decrease in Tregs present in tumors, draining lymph nodes and
spleen and improved long-term survival (50% of mice survived .150 days). No improvement in survival was observed when
Tregs were depleted 24 days after tumor implantation, suggesting that tumor burden is an important factor for determining
efficacy of Treg depletion in clinical trials. In a T cell dependent model of brain tumor regression elicited by intratumoral
delivery of adenoviral vectors (Ad) expressing Fms-like Tyrosine Kinase 3 ligand (Flt3L) and Herpes Simplex Type 1-
Thymidine Kinase (TK) with ganciclovir (GCV), we demonstrate that administration of PC61 24 days after tumor implantation
(7 days after treatment) inhibited T cell dependent tumor regression and long term survival. Further, depletion with PC61
completely inhibited clonal expansion of tumor antigen-specific T lymphocytes in response to the treatment.
Conclusions: Our data demonstrate for the first time, that although Treg depletion inhibits the progression/eliminates GBM
tumors, its efficacy is dependent on tumor burden. We conclude that this approach will be useful in a setting of minimal
residual disease. Further, we also demonstrate that Treg depletion, using PC61 in combination with immunotherapy,
inhibits clonal expansion of tumor antigen-specific T cells, suggesting that new, more specific targets to block Tregs will be
necessary when used in combination with therapies that activate anti-tumor immunity.
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Introduction
Glioblastoma multiforme (GBM) is a deadly primary brain
tumor which is highly invasive with tumor cells infiltrating the
surrounding healthy brain tissue [1]. The median survival of
patients diagnosed with GBM is one year (4–6 months after
recurrence), with less than 5% of the patients remaining alive 5
years after diagnosis [2]. Improvements in surgery, chemotherapy
and radiotherapy have not been translated into significantly
improved prognosis for patients with GBM; long term survival (5
years after diagnosis) has not improved since 1950 [3]. Tumor
recurrence almost always occurs even if surgery successfully
removes the majority of the primary tumor mass. Novel therapies
to prevent or treat tumor recurrence are urgently needed to treat
patients diagnosed with GBM.
Immunotherapy has been proposed as a powerful approach to
prevent tumor recurrence by eliminating tumor cells while sparing
normal surrounding healthy cells [4,5]. Several clinical trials are
now underway to test whether immunotherapy is safe and effective
to treat GBM [6,7]. GBMs over express tumor antigens such as
MAGE, Her2/neu, Tyrosinase, Trp-1, Trp-2, gp100, IL13Ra2,
Survivin (reviewed in [8]) and EphA2 [9]. The immune system
ordinarily sculpts tumors resulting the loss of tumor antigen
expression [10,11], however, the location of GBM in the brain, a
site of immune privilege [12,13], or the presence of a highly
immunosuppressive environment in brain tumors [14,15] may be
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1983Figure 1. Intracranial GBM tumors are densely infiltrated with immune cells. (A) GL26 tumor volume 7, 14 and 21 days after implantion into
the brain striatum of C57BL/6 mice was determined. Reactive astrocytic staining (GFAP+) was used to define the border of the tumor with non-
malignant brain tissue. Representative sections of mouse brains bearing tumors implanted 7, 14 and 21 days previously and stained with GFAP are
shown on the left. Tumor growth kinetics were essentially exponential over the time period analyzed with a doubling time of approximately 1.8 days.
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patients. Autologous dendritic cells (DC) loaded with GBM tumor
peptides [16] or autologous tumor lysate [17] have been used to
vaccinate patients in two recent Phase I clinical trials. No
significant increase in survival was observed using autologous
tumor lysates [17]. However, the median time to progression and
median survival of patients treated with peptide based vaccines
was increased compared with patients that were treated during the
same time period with conventional therapies [16]. Interestingly, a
subpopulation of responders to the treatment were identified by
the expression of low concentrations of TGFb in the brain.
Intratumoral expression of TGFb can suppress adaptive immune
responses against antigen [4,5] and was predictive of clinical
outcome after vaccination [16]. In addition, circulating tumor
antigen specific CD8
+ T lymphocytes have been identified in
GBM patients [18], but the immunosuppressive environment in
the tumor prevents the elimination of GBM from these patients.
T cell responses against tumor antigen measured by tetramers
and ELISPOT do not always correlate with tumor regression in
clinical trials testing immunotherapies for human GBM [19]. This
suggests that suppression of effective immune responses against
tumor antigens can interfere with immune dependent tumor
regression. Recently, researchers have investigated whether
depletion of a subset of T lymphocytes called regulatory T
lymphocytes (Tregs) can potentiate immunotherapies against
cancer. Tregs are a subpopulation of CD4
+ T lymphocytes that
constitutively express the transcription factor Foxp3, the high
affinity IL2 receptor CD25 and the B7 ligand CTLA4 [20]. Tregs
are required for the maintenance of tolerance throughout the
lifetime of the organism [21] and mutations in Foxp3 are known to
cause acute autoimmune disorders in humans [22]. Foxp3
+ Tregs
accumulate within human gliomas during tumor progression[23]
and have been found to correlate with tumor grade [24]. Survival
was improved when Tregs were depleted from GL261 tumor
bearing mice using CD25 antibodies administered 7 days after
tumor implantation and three times per week for 3 weeks
thereafter [25]. Also, administration of CD25 depleting antibodies
were also shown to improve survival when administered in
combination with DC transfected with tumor mRNA in a GBM
model [26].
We have recently developed a combined gene therapeutic
approach aimed at engineering the tumor microenvironment to
induce the migration into the tumor mass of APCs and elicit tumor
cell death [27]. Our approach consists of expressing Fms-like
tyrosine kinase 3 ligand (Flt3L) which induces dendritic cell (DC)
infiltration into the brain parenchyma [28] in combination with
the conditional cytotoxic gene Thymidine Kinase (TK) [27,29],
which in the presence of GCV induces tumor cell death. This
combined approach induces T cell dependent tumor regression
[27]. We wished to assess the effects elicited by depletion of Tregs;
on tumor progression in untreated GBM bearing mice and on T
cell-dependent brain tumor regression elicited by Ad-Flt3L and
Ad-TK treatment. Our data demonstrated that depletion of Tregs
using the CD25 specific hybridoma PC61 induced tumor
regression and long term survival when administered 15 days
after tumor implantation, independent of tumor antigen specific T
lymphocytes. In combination with intratumoral delivery of Ad-
Flt3L and Ad-TK, however, we found that PC61 administration
24 days after tumor implantation (7 days after treatment)
completely suppressed adaptive immune responses against GL26
tumor antigens. In addition to Tregs, CD25 is also expressed on
the cell surface of precursor B and T lymphocytes and a mature
subpopulation of DC [30] and is also upregulated on the cell
surface of activated T lymphocytes and B lymphocytes [31]. In our
model, administration of CD25-antibodies also eliminated acti-
vated, CD25
+ T lymphocytes and prevented clonal expansion of
tumor antigen specific T cells. Our data suggest that the use of
PC61 aiming at Treg depletion could reduce the efficacy of
immunotherapeutic regimes by suppressing activation and clonal
expansion of tumor antigen specific T lymphocytes.
Results
Syngeneic intracranial GBM tumors are densely infiltrated
with Immune cells, including Tregs
Accumulation of Foxp3
+ Tregs in human gliomas correlates
with the grade of the tumor and patient survival [24].
Accumulation of Foxp3
+ Tregs in syngeneic mouse gliomas has
also been described and depletion of Tregs with CD25-specific
immunoglobulins can induce tumor regression and improve
survival in these preclinical models [25,32,33]. In order to
investigate whether Treg depletion could improve therapeutic
outcome in combination with immunotherapy/gene therapy, we
first established whether Tregs infiltrated into the syngeneic mouse
glioma arising from the intracranial implantation of GL26 cells
into the brain striatum. Implantation of syngeneic GL26 cells
reproducibly led to the linear growth of tumors (R
2.0.99) with a
mean tumor volume of approximately 0.5mm
3 at day 15 and 30
5 mice were used to determine tumor volume at each time point. (B) Infiltration of immune cells in intracranial GL26 tumors. Brain sections from
tumor bearing mice were stained with antibodies against CD45 (leukocytes) or F4/80 (macrophages/activated microglia). Representative Confocal
images show immune cells (green) within the tumor mass and in the tumor borders. DAPI (blue) was used to stain nuclei. Yellow arrows indicate
immunoreactive cells. T: tumor. (C) Tumor infiltrating immune cells were isolated from tumors 24 days after tumor implantation and analyzed using
flow cytometry. (i) Dot plot of CD11c against I-Ab that was first gated for live CD45+ leukocytes. DC (CD11c+ CD45+ I-Ab+) are shown in the red box.
(ii) Macrophages (MW) were assessed by gating live leukocytes with CD45, then plotting CD11b against I-Ab. The red box outlines the population of
tumor infiltrating macrophages (CD11b+ CD45+ I-Ab+). (iii) T cells were stained with CD3e-PE, CD4-PerCP and CD8a-FITC. The plot displays CD4
against CD8a when cells were first gated for CD3e+ live leukocytes. CD4+ T cells and CD8a+ T cells are shown in red boxes. (iv) Tumor infiltrating
Tregs were observed by staining with CD3e-PE, CD4-PerCP and Foxp3-FITC. CD3e+ live leukocytes were gated and dot plots display Foxp3 against
CD4 staining. The population of Tregs (CD4+ Foxp3+ CD3e+) are shown in the red box. (v) NK and NK-T cells were visualized by gating live CD45+
leukocytes, then displaying NK1.1 against CD3e. The population of tumor infiltrating NK cells (CD3e- CD45+ NK1.1+) and NK-T cells (CD3e+ CD45+
NK1.1+) are shown in red boxes. (vi) Tumor infiltrating B cells are visualized by gating for live leukocytes, then plotting CD45 against CD19. The
population of B cells (CD19+ CD45+) is shown in a red box. The percentages of each immune cell population infiltrating the tumor with respect to the
total number of tumor CD45+ cells is indicated in representative dot plots. (D) Nissl staining was used to visualize tumors in the brain. Tumors are
dense in Nissl substance, so stain darker than normal brain tissue. Representative Confocal images show tumor infiltrating CD4+ T cells, CD8+ T cells,
CD205+ mDCs, CD19+ B cells, and CD25+ immune cells (seen in green) and DAPI (blue) was used to visualize the nuclei. Yellow arrows indicate
immunoreactive cells. (E) Flow cytometric analysis of the percentage of T cells that express CD25 in spleens, dLN and tumors in mice bearing
intracranial GL26 brain tumors 24 days after tumor implantation. (F) Representative dot plots of CD25 vs CD3e in immune cells isolated from the
spleen, LN and tumor. The percentages of CD25+ cells population with respect to the total number of CD3e+ cells in the tumor, draining lymph
nodes or spleen are indicated in representative dot plots.
doi:10.1371/journal.pone.0001983.g001
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PLoS ONE | www.plosone.org 3 April 2008 | Volume 3 | Issue 4 | e1983Figure 2. PC61 does not affect the viability or proliferation of GL26 cells in vitro or in vivo. (A) GL26 cells were incubated for 48 h with
100 mg/ml PC61 or 100 mg/ml rat IgG1 isotype control. Cells were then harvested and stained with Annexin V-FITC and Propidium Iodide to identify
apoptotic cells. No significant increase in apoptosis was noted when cells were incubated with PC61 or isotype control immunoglobulins compares
with untreated controls (p.0.05). A large increase in apoptosis was observed when cells were incubated for 4 h with H2O2 (p,0.001). Error bars
represent the standard error from 3 replicates and the assay was repeated 3 times. One Way ANOVA with Tukey’s post test was used to calculate
significant differences (***p,0.001). (B) Proliferation of GL26 cells was measured by detecting BrdU incorporation into DNA. No significant difference
in proliferation was observed (p.0.05) when cells were incubated with PC61 (rat IgG1aCD25) compared with isotype controls (rat IgG1), or untreated
cells (***p,0.001 compared to negative (no cells) control, ns=non significant). (C) Athymic nu/nu mice (Balb/c background) were challenged with a
single intracranial injection of GL26 cells and treated 15 d later with 1mg either PC61 or isotype control immunoglobulins injected i.p. Survival was
monitored and mice were euthanized when moribund. No significant difference in survival was observed using a log rank test (p.0.05) (n=5).
doi:10.1371/journal.pone.0001983.g002
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PLoS ONE | www.plosone.org 4 April 2008 | Volume 3 | Issue 4 | e1983Figure 3. Depletion of Tregs 15 days post-tumor implantation induces brain tumor regression. (A) Diagram depicting the different
treatments administered to 4 cohorts of tumor bearing mice. GL26 cells were implanted in the brain of all mice on day 0 and were treated by the
intratumoral delivery of saline on day 17 with depletion of CD25
+ cells using PC61 on day 15 (green) or on day 24 (red). Control groups of tumor
bearing mice received rat IgG1 isotype control on day 15 (blue), or no systemic administration of immunoglobulins (Black) as indicated. Mice were
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3) at day 24 (Fig. 1A). These tumors exhibit
profuse infiltration of CD45
+ and F4/80
+ cells, which are evident
throughout the tumor mass and also at the borders (Fig 1B).
Immune cell infiltration into the tumors was also assessed by flow
cytometry 24 days after tumor implantation (Fig. 1 C). We
detected tumor infiltrating mDC (CD11c
+ CD45
+ I-A
b+, Fig. 1Ci)
and MW (CD11b
+ CD45
+ I-A
b+, Fig. 1Cii) that represented 3.5%
and 19% of the total number of CD45+ immune cells present in
the tumor respectively. Lymphocytes were also identified and
constituted ,80% of the total number of CD45+ immune cells
infiltrating the tumors (Fig. 1 C iii-vi). These included CD4
+ T
cells (CD3e
+ CD4
+ CD8a
2, 26%), CD8a
+ T cells (CD3e
+ CD4
2
CD8a
+, 18%), Foxp3
+ Tregs (CD3e
+ CD4
+ Foxp3
+, 8.4%), NK
cells (CD3e
2 NK1.1
+ CD45
+, 18%), NK-T cells (CD3e
+ NK1.1
+
CD45
+, 7%) and B cells (CD3e
2 CD19
+ CD45
+, 5%). The
presence of CD4
+, CD8a
+, CD19
+ lymphocytes as well as CD205
mDC were also observed by immunofluorescence (Fig. 1 D). In
addition, large numbers of lymphocytes that were immunoreactive
for CD25 were observed within the tumor using confocal
microscopy (Fig. 1 D) and flow cytometry (CD3e
+ CD25
+
CD45
+) (Fig. 1 E, F). Moreover, the percentage of CD3e
+ T cells
that expressed cell surface CD25 was ,40% of the total number of
tumor infiltrating T cells and was greatly elevated in the draining
(cervical) lymph node (dLN) (p,0.05) and tumor (p,0.01) when
compared with the spleen of tumor bearing mice (Fig. 1 E).
Depletion of Tregs using PC61 induces brain tumor
regression but also reduces T cells in tumor and dLN
Considering that we detected extensive infiltration of T regs
within the intracranial GL26 tumors, we aimed to deplete this
immune cell population in order to determine their effect on
tumor cell progression and on anti-tumor immune response
induced by a T-cell dependent immunotherapeutic approach, i.e.
Ad-Flt3L/TK. The rat IgG1 hybridoma PC61 was found to bind
with mouse high affinity IL-2 receptor (CD25) [34] and in vivo
administration of PC61 to mice causes the depletion of Tregs for
more than a week [33,35]. Thus, we used this antibody to induce
T reg depletion in vivo in a syngeneic mouse intracranial glioma
model. We first determined whether PC61 would affect tumor cell
viability and growth in vitro and in vivo. Incubation of GL26 cells
with PC61 did not affect GL26 cell viability (Fig. 2A) or
proliferation in vitro (Fig. 2B). We then administered PC61 or
isotype control IgG to tumor-bearing athymic nu/nu mice, which
have been shown to be deficient in T regs [26,36]. Tallying with
other reports [26], we found that tumor growth in T reg deficient
nu/nu immune deficient mice was not affected by PC61; both
isotype control or PC61-injected mice succumbed due to tumor
burden 18-22 days after tumor implantation.
After ruling out any direct effect of PC61 on tumor cell growth
we studied the effect of T reg depletion in wild type C57/B6 mice
bearing intracranial GL26 glioma. The experimental paradigm
used is depicted in Fig. 3A. Depletion of Tregs 15 days after tumor
cell implantation significantly increased the number of long term
survivors with 40% of mice were still alive 150 days later (p,0.05,
Fig. 3B). This was more than 5 times longer than the mean
survival of control tumor bearing mice (Fig. 3B). No significant
increase in long term survival was observed when Tregs were
depleted in larger tumors (24 days) (p.0.05) and only 10% of mice
survived long term from this group (Fig. 3B). Interestingly, we did
not observe any DTH responses when we injected irradiated
GL26 cells into the footpad of long term survivors from Treg
depleted mice (Fig. 3C). In order to assess the effects of treatment
with PC61 in vivo, we analyzed the presence of Foxp3
+ CD4
+
Tregs infiltrating the GBM mass as well as in the draining lymph
nodes and the spleen after intraperitoneal injection of PC61 (days
15 and 24) or the rat IgG1 isotype control (day 15 days) into tumor
bearing mice. PC61 injection on day 15 led to a 9 fold reduction
(p,0.001) in the number of tumor infiltrating Tregs when
measured using flow cytometry 12 days later (day 27), and
injection of PC61 on day 24 led to the almost complete depletion
of Tregs (p,0.001) in the tumor 3 days later (day 27) (Fig. 3D). As
expected, peripheral Treg populations in the draining lymph
nodes (Fig. 3E) and spleens (Fig. 3F) were also significantly reduced
compared with isotype treated controls (p,0.001). Interestingly,
we observed a 3 fold decrease in the absolute percentage of CD4
+
T cells (Fig. 4A) and CD8a
+ T cells (Fig. 4B) infiltrating into the
tumor after administration of PC61. Furthermore, PC61 signifi-
cantly depleted populations of CD4
+ T cells (p,0.05, Fig. 4C) and
CD8
+ T cells (p,0.01, Fig. 4D) in the tumor draining lymph
nodes. There was no change noted in the percentages of CD4
+ T
cells and CD8a
+ T cells in the spleen (p.0.05, Fig. 4E–F) and MW
and DC remained unchanged in tumors and draining lymph
nodes although increased slightly in spleen (Fig. 5).
Treatment with PC61 prevents activation of adaptive
anti-tumor immune responses and inhibits tumor
regression when used in combination with Ad-Flt3L and
Ad-TK
We also aimed to investigate the effects of depletion of Tregs
using an anti-CD25 immunoglobulin on the efficacy of the T cell-
dependent immunotherapy mediated by intratumoral delivery of
Ad-Flt3L and Ad-TK [27,37]. Activated CD4
+ and CD8
+ T
lymphocytes upregulate cell surface CD25 after initial binding of
the TCR with antigen displayed on MHC [30,31] and this might
explain the apparent decrease in T cells that was observed in
tumors (Fig. 4A–B) and dLN (Fig. 4C–D) following administration
of PC61. To investigate this further, and determine whether
elimination of Tregs using PC61 could adversely affect T cell
dependent immunotherapy of GBM, we implanted tumors in the
striatum on day 0 and mice were treated with Ad-Flt3L and Ad-
TK 17 days later, whilst PC61 or isotype control immunoglobulins
were administered to groups on day 15 or day 24 (Fig. 6A). When
we injected Ad-Flt3L and Ad-TK into the tumor on day 17 (when
used either for survival studies, or euthanized at day 27 post-tumor implantation for analysis of immune cell populations by flow cytometry. (B)
Kaplan-Meier curve displaying survival of the 4 groups of mice described in (A). Ten mice were used in each group and a log-rank test was used to
calculate significance between untreated group and PC61 treated groups. *p,0.05 compared with untreated mice and isotype control treated mice.
(C) DTH test was performed on long-term survivor mice 100 d after tumor implantation. Mice had originally been treated with PC61 on day 15 (green
lines). Irradiated GL26 cells in PBS in the right rear footpad (filled box) or PBS control in the left rear footpad (open box) of mice. The thickness of the
footpad was determined 0 h, 4 h, 24 h and 48 h after injection of irradiated cells or PBS. Two Way ANOVA with Tukey’s post test was used to
calculate significant differences. (D–F) Tregs (CD3e
+ CD4
+ Foxp3
+) infiltrating tumors (D), draining lymph nodes (E) or spleens (F) were quantified in
mice administered rat IgG1 isotype control (iso) or PC61 on day 15 (15) or day 24 (24) as indicated in the graphs (left). Dot plots (right) display
representative data from 5 mice per group. The percentages of T regs with respect to the total number of CD45+ cells in the tumors, draining lymph
nodes (dLN) or spleen are indicated in representative dot plots. One Way ANOVA with Tukey’s post test were used to determine significant
differences (***p,0.001).
doi:10.1371/journal.pone.0001983.g003
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3 in size (Fig. 1A) we observed a robust
increase in survival with 50% of mice alive 150 d later (p,0.01,
Fig. 6B) that was not adversely affected by administration of rat
IgG1 isotype control (p.0.05). PC61 administered 2 days before
injection of Ad-Flt3L and Ad-TK reduced survival to 30%,
although this was not statistically different from isotype treated
controls (p.0.05, Fig. 6B). However, when we treated mice with
Ad-Flt3L and Ad-TK on day 17 and depleted Tregs on day 24, we
found that long term survival was significantly reduced compared
with mice that did not receive PC61 (p,0.05, Fig. 6B). Only 10%
of tumor bearing mice survived 150 days later, suggesting that
administration of PC6 17 d after intratumoral delivery of Ad-
Flt3L and Ad-TK adversely affects T cell dependent brain tumor
regression. In long term survivors after treatment with Ad-Flt3L
and Ad-TK, a DTH response to irradiated GL26 cells in the
footpad was observed when mice had been administered either
PC61 (p,0.01) or isotype controls (p,0.001) (Fig. 6C). Moreover,
treatment of tumor bearing mice with Ad-Flt3L and Ad-TK
induced a robust increase in the total number of tumor responsive
T cells that secreted IFNc when co-incubated with BMDC loaded
with GL26 cell extracts (p,0.001, Fig. 6D). Interestingly we did
not observe any increase in IFNc secreting T lymphocytes in
response to BMDC loaded with GL26 cell extracts when PC61
was injected either prior to (15 days) or post (24 days) treatment
using Ad-Flt3L and Ad-TK (p.0.05, Fig. 6D). The number of
tumor infiltrating Tregs was reduced after systemic delivery of
PC61 (p,0.001, Fig. 6E) and the percentage of Tregs was also
significantly reduced in dLN and spleen, (p,0.001, Fig. 6F–G)
irrespective of whether the mice were treated with saline or with
Ad-Flt3L and Ad-TK.
Treatment with PC61 prevents increases in tumor
infiltrating T cells and MW but not DCs following
treatment with Ad-Flt3L and Ad-TK
In agreement with others, our data indicate that systemic
delivery of PC61 causes the depletion of Foxp3
+ Tregs [25,33,35].
Our results demonstrate that PC61 interferes with the induction of
adaptive immune responses against brain tumor antigen. Further,
administration of PC61 depleted 60% of spleen CD25
+ T cells
(Fig. 7A). Since clonal expansion of tumor antigen specific T cells
induced by Ad-Flt3L-TK was inhibited by PC61 administration,
we next determined whether PC61 affects the influx of CD4
+ and
CD8a
+ T cells into the tumor, the draining lymph nodes and the
spleen after treatment with Ad-Flt3L and Ad-TK (Fig. 7 B). The
total number of CD45
+ tumor infiltrating immune cells increased
10 d after intratumoral delivery of Ad-Flt3L and Ad-TK
(p,0.001, Fig. 7 C), as did the numbers of CD4
+ T cells
(p,0.001, Fig. 7 D) and CD8a
+ T cells (p,0.001, Fig. 7 E). This
observation was consistent with the induction of adaptive immune
responses against tumor antigen by intratumoral delivery of Ad-
Flt3L and Ad-TK. Co-administration of PC61 either on day 15 or
day 24, however, completely blocked the Ad-Flt3L and Ad-TK
dependent increase in total numbers of tumor infiltrating immune
cells (p.0.05, Fig. 7 C), and CD8a+ T cells (p.0.05, Fig. 7 E).
Increased tumor infiltrating CD4+ T cells following treatment
with Ad-Flt3L and Ad-TK was only inhibited when PC61 was
administered on day 24 (p.0.05, Fig. 7 D). No changes were
observed in the number of T cells in the dLN (Fig. 7 F–G) or
spleen (Fig. 8). Moreover, increase in numbers of tumor infiltrating
macrophages (p,0.01, Fig. 9 A) was also blocked by PC61
administration but infiltration of mDCs into tumors after
administration of Ad-Flt3L and Ad-TK (p,0.001, Fig. 9B) was
not suppressed. Together, our data suggest that infiltration of
mDC was an early event, probably induced by expression of Flt3L,
whereas infiltration of T cells occurred later and was dependent on
the successful initiation of adaptive immune responses against
tumor antigens. MW increased in dLN and spleen, while mDC
only increased significantly in the spleen (Fig. 9 C–F).
Discussion
Elimination of Tregs using depleting antibodies in combination
with existing immunotherapies has been proposed to enhance anti-
tumor immunity [38]. Herein we show in a syngeneic mouse
model of GBM that depletion of Tregs using PC61, a CD25
specific immunoglobulin can also deplete activated T cells, and in
doing so can interfere with the clonal expansion of tumor antigen
specific T cells during immunotherapy. In agreement with
previous reports [23,24,33,35,39,40], we observed that tumors,
and dLN were heavily infiltrated with CD25
+ T cells. Previously, it
was shown that administration of 250 mg CD25-depleting
immunoglobulins 3 days before tumor implantation [32] and
long-term administration of CD25-depleting immunoglobulins
after tumor implantation (0.5 mg/injection, beginning 1 week after
tumor implantation and given three times per week for 3 weeks)
[25] can induce long term survival in about half of GL261 tumor
bearing C57BL/6 mice. To determine the role of Tregs in tumor
regression in a clinically relevant scenario of a large, pre-
established tumor mass, we gave a single dose of PC61 hybridoma
at two time points, either day 15 when the tumor was
approximately 0.5mm
3 or day 24 when the tumor was 15mm
3.
Herein we show that elimination of CD25
+ T lymphocytes by a
single injection of PC61 15 days after tumor implantation
mediated tumor regression and improved long term survival in
almost 50% of mice. However, Treg depletion increased the
survival of tumor bearing mice only if depletion was done when
the tumors were very small, i.e., 0.45mm
3. Our findings are in
agreement with other reports that show an anti-tumor effect of T
reg depletion in mouse models of neuroblastoma [41], leukemia,
fibrosarcoma, myeloma [35], and glioma [25,32]. We observed
that the antitumor effects of Treg depletion were not mediated by
a T cell dependent anti-tumor immune response. Our results show
that Treg depletion did not generate tumor-specific T cells as assed
by ELISPOT assay nor did it induce anti-tumor immunological
memory. These data suggest that the innate immune system could
Figure 4. Infiltrating CD4+ T cells and CD8a+ T cells decrease in the tumor and dLN after treatment with PC61. C57BL/6 mice were
challenged with tumor cells on day 0, and treated on day 17 by intratumoral delivery of saline. Tregs were depleted on either day 15 or day 24 by ip
injection of PC61. Immune cells were isolated from the spleen, the cervical LN and the intracranial tumor at day 27 post-tumor implantation to
determine the percentage of CD4+ T cells and CD8a+ T cells in each tissue. The percentage of tumor infiltrating immune cells that were CD4+ T cells
(CD3e+ CD4+ CD8a-) (A) and CD8a+ T cells (CD3e+ CD4- CD8a+)( B); the percentage of immune cells in the draining lymph nodes that were CD4+ T
cells (CD3e+ CD4+ CD8a-) (C) and CD8a+ T cells (CD3e+ CD4- CD8a+)( D); and the percentage of immune cells in the spleen that were CD4+ T cells
(CD3e+ CD4+ CD8a-) (E) and CD8a+ T cells (CD3e+ CD4- CD8a+)( F) are shown in graphs (left). Representative dot plots for each treatment group are
displayed on the right (gated for live leukocytes with FSC vs SSC and CD3e+ T lymphocytes). The percentages of each immune cell population with
respect to the total number of CD45+ cells in the tumors, draining lymph nodes (dLN) or spleen are indicated in representative dot plots. One Way
ANOVA with Tukey’s post test were used to calculate significant differences. (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0001983.g004
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this model. In fact, T regs have been shown to inhibit the activity
of the innate immune system by directly suppressing the cytotoxic
effect of NK cells [42]. This inhibitory mechanism is dependent on
TGF-b and cell-cell contacts [42–45]. Since we found that NK
cells comprise ,20% of the immune cells that infiltrate GL26
intracranial tumor, the cytotoxic activity of these cells could be
involved in the antitumor effects observed after T reg depletion at
day 15 after tumor implantation. Interestingly, no increase in
survival was observed when PC61 was administered to tumor
bearing mice 24 days after tumor implantation, this was probably
due to the size of the tumor and the relatively short life expectancy
of these mice (,5 d to death). It is likely that the tumor burden will
be an important factor in the clinic when patients are treated by
depletion of Tregs, we would expect from these data that Treg
depletion might show efficacy when treating minimal, residual
tumors.
Further, we wished to determine whether depletion of Tregs
with CD25-specific immunoglobulins would affect survival when
implemented in combination with intratumoral delivery of Ad-
Flt3L and Ad-TK. Along these lines, it has been reported that
depletion of Tregs using PC61 improved survival when GBM
bearing mice were vaccinated with DC transfected with tumor cell
mRNA [26]. However, that study assessed the prophylactic, not
therapeutic effects of PC61 against brain tumors; since tumor cells
were implanted 10 days after depletion of Tregs and 7 days after
vaccination with DC pulsed with tumor cell mRNA [26]. In our
model, tumors were already well established (17 days) prior to
intratumoral delivery of Ad-Flt3L and Ad-TK to induce T cell-
dependent tumor regression. Administration of PC61, 2 days
before treatment (15 days after tumor implantation) induced
tumor regression in about 50% of mice which was not significantly
different to treatment with Ad-Flt3L and Ad-TK alone. However,
when PC61 was administered 7 days after injection of Ad-Flt3L
and Ad-TK, therapeutic improvement in survival was almost
completely abolished, due to the depletion and/or functionally
inactivated tumor antigen specific T lymphocytes that had become
activated in response to the therapy. Our results highlight that
depletion of Tregs by targeting CD25 might interfere with the
induction of adaptive immune responses against brain tumor
antigen.
A cell surface marker specific for Tregs that could be targeted
with immunoglobulins to specifically deplete Tregs would
beneficial to overcome immunological tolerance/ignorance to
brain tumor antigens. Unfortunately, the cell surface proteins on
Tregs (for example; CD25, CTLA4) are also expressed on other
immune cells such as activated T lymphocytes [46]. CTLA4 has
also been widely studied as a target to specifically deplete Tregs.
Intracellular CTLA4 is expressed at high levels in Tregs and is also
expressed at much lower levels on the cell surface of resting Tregs.
Activation of Tregs stimulates the upregulation of CTLA4 on their
cell surface and may thus be a useful target to specifically inhibit
Tregs. Depletion of Tregs using immunoglobulins against CTLA4
has been found to improve survival in mouse models of glioma
[47]. CTLA4 is also expressed in the ER of helper and effector T
lymphocytes and cell surface expression is upregulated 24 to 48 h
after activation of TCR [48]. It remains to be investigated,
however, whether CTLA4 depletion might also interfere with the
clonal expansion of tumor-antigen specific T lymphocytes.
Our results suggest that while elimination of Tregs might be
sufficient to eliminate smaller tumors, the depletion of Tregs using
CD25-targetting strategy might interfere with the clonal expansion
of tumor antigen specific T lymphocytes if used in combination
with another immunotherapeutic strategy. Foxp3 is currently the
only marker that has been identified that is exclusively expressed
on Tregs and not on other immune cells. However, Foxp3 is
intranuclear and therefore cannot be easily depleted using
immunoglobulins. Further study on the mechanism of action of
Foxp3 and/or cell surface Treg specific markers might highlight
molecular targets that could be useful to specifically eliminate
Tregs. Our results indicate that clinical trials which propose to
utilize CD25 depleting antibodies, or similar Treg depleting
approaches, must carefully monitor the effects on normal activated
T cells, and adjust dosing schedules accordingly. Further, the use
of Treg depleting strategies will only be useful in the context of
minimal residual disease.
Materials and Methods
Adenoviral vectors, Cell Lines, plasmids, and reagents
We used first generation, recombinant adenoviral vectors
(serotype 5) expressing Herpes Simplex Virus Type I Thymidine
Kinase (Ad-TK) [27,29] and Fms-like tyrosine kinase 3 ligand (Ad-
Flt3L)[28,49] in this study. The methods for adenoviral genera-
tion, purification, characterization and scale up have been
previously described by our lab[27,29,49]. GL26 cells were
obtained from ATCC (Manassas, VA) and were grown in DMEM
culture media supplemented with 10% FCS and 1% Pen-Strep
and passaged routinely every 2-3 days. Ascites fluid from the PC61
hybridoma was purchased from BioExpress Cell Culture Services
(West Lebanon, NH) and isotype rat IgG1 control was purchased
from Sigma (St Louis MO). Foxp3-FITC was purchased from
ebioscience, primary antibodies for immunofluorescence and
immunohistochemistry (CD45, F4/80, CD205, CD4, CD8,
CD19, CD25 and GFAP) were all purchased from Serotec and
biotinylated secondary antibodies were purchased from Dako
(Denmark) and fluorescent tagged secondary antibodies were
purchased from Invitrogen (Carlsbad, CA). All antibodies used for
flow cytometry were purchased from BD Pharmingen (San Diego,
CA). Recombinant human Annexin V-FITC was purchased from
BenderMedSystems (Vienna, Austria) and the BrdU DNA labeling
and detection kit was procured from Exalpha Biologicals Inc
(Maynard MA). All other chemicals were purchased from Sigma.
Mouse glioblastoma model
Wild type C57BL/6J mice were purchased from Jackson
Laboratories (Bar Harbor, ME, USA). To establish a syngeneic
tumor model, we used GL26 cells that were derived from a
chemically induced glioma in a female C57BL/6 mouse. Female
mice (6–12 weeks) were anesthetized with an IP injection of
Ketamine (75 mg/kg) and Medetomidine (0.5 mg/kg), placed in a
stereotactic apparatus modified for mice, and a hole was drilled in
Figure 5. Antigen presenting cells do not change in tumor or dLN in untreated animals but increase in spleen after depletion of
Tregs with PC61. GL26 cells were implanted in the brain striatum of C57BL/6 mice. Rat IgG1 isotype control immunoglobulins (-) were administered
on day 15 and PC61 was administered on day 15 or day 24 as indicated. The percentage of tumor infiltrating macrophages (MW; CD11b+ CD45+ I-
Ab+)( A,C,E) and myeloid Dendritic cells (mDC; CD11c+ CD45+ I-Ab+)( B,D,F) were quantified at day 27 post-tumor implantation using flow
cytometry in the tumor (A,B) dLN (C,D) and spleen (E,F). The percentages of each immune cell population with respect to the total number of
CD45+ cells in the tumors, draining lymph nodes (dLN) or spleen are indicated in representative dot plots. 5 and 10 mice were analyzed per group.
One Way ANOVA with Tukey’s post test was used to determine statistical significance.
doi:10.1371/journal.pone.0001983.g005
CD25 Depletion in Glioma
PLoS ONE | www.plosone.org 10 April 2008 | Volume 3 | Issue 4 | e1983Figure 6. PC61 prevents activation of adaptive anti-tumor immune responses using Ad-Flt3L and Ad-TK. (A) C57BL/6 mice were
challenged with tumor cells on day 0, and treated on day 17 by intratumoral delivery of Ad-Flt3L and Ad-TK or saline as indicated. Tregs were
depleted on either day 15 (green) or day 24 (red) by ip injection of PC61 or on day 15 with the isotype control (blue). Immune cells were isolated from
the spleen, the cervical LN and the tumor. Mice were either used for survival studies or euthanized on day 27 for analysis of immune cell populations
by flow cytometry and ELISPOT. (B) Kaplan-Meier curve displaying survival data from 10 mice per group. Statistically significant differences to Ad-
Flt3L and Ad-TK treated mice only (black line, no PC61 depletion) were calculated using the log-rank test (*p,0.05, **p,0.01). Administration of PC61
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unilaterally into the right striatum (+0.5 mm AP, +2.2 mm ML,
23.0 mm DV from bregma) using a 5 ml Hamilton syringe with a
33-gauge needle. The needle was left in place for 3 minutes prior
to removal to allow tumor cells to settle at the injection site. Mice
were resuscitated using atipamazole (IP) and administered
buprinex (SQ dose) as an analgesic. 17 days after tumor
implantation and using the same stereotactic coordinates, mice
received an intratumoral injection of 5610
8 iu Ad-Flt3L and
5610
7 iu Ad-TK in 1 ml saline. Alternatively, mice were injected
with 1 ml saline as a control. Mice treated with Ad-Flt3L and Ad-
TK also received 25 mg/kg GCV (IP, Roche, Boulder CO) twice
daily for 7 days starting the day after vector injection. CD25
+
Tregs were depleted by a single ip injection of 1mg ascites fluid
(600 ml) from the PC61 hybridoma. Alternatively GL26 tumors
were implanted into female T reg deficient athymic nude mice
(Simonsen labs) and PC61 or control IgG was administered ip 15
days later as described. All animals were housed in specific
pathogen free environment, and were closely monitored All
animal experiments were performed after prior approval by the
Institutional Animal Care and Use Committee at Cedars-Sinai
Medical Center and conformed to the policies and procedures of
the Cedars-Sinai Medical Center Comparative Medicine Depart-
ment. Mice used in this study were monitored for signs of
moribund behavior and euthanized when their health status
reached criteria established by the guidelines of the IACUC.
Animals were euthanized at first signs of moribund behavior, by
terminal perfusion with oxygenated, heparinized Tyrode’s solution
(132 mM NaCl, 1.8 mM CaCl2, 0.32 mM NaH2PO4, 5.56 mM
glucose, 11.6 mM NaHCO3, and 2.68 mM KCl) and were fixed
with 4%PFA in PBS for immunofluorescence and immunohisto-
chemistry.
Immunohistochemistry and Immunofluorescence
Fifty micrometer-thick coronal sections were cut through the
striatum using a vibratome. Free-floating immunohistochemistry
was performed to detect inflammatory and immune cell markers.
Endogenous peroxidase was inactivated with 0.3% hydrogen
peroxide (only for IHC). Sections were subjected to antigen
retrieval by incubation in 10mM Citrate at 60uC for 10 minutes
before washing and blocked with 10% horse serum (Life
Technologies, Carlsbad, CA) in TBS+0.5% Triton X-100 (Sigma)
before incubating for 72 h with primary antibodies CD45
(1:1000), F4/80 (1:1,000), CD205 (1:500), CD4 (1:1000), CD8a
(1:5,000), CD19 (1:1000), CD25 (1:500) and GFAP (1:1000).
Biotinylated secondary antibodies for IHC (Dako) were incubated
with sections (1:1,000 in 1% horse serum in TBST) for 4 h and
detected using the Vectastain Elite ABC horseradish peroxidase
method (Vector Laboratories, Burlingame, CA). Immunoreactive
cells were developed with diaminobenzidone (Sigma) and glucose
oxidase (Sigma). Sections were mounted on gelatinized glass slides
and dehydrated through graded ethanol solutions. Secondary
antibodies for IF (Alexa-488 conjugated) were purchased from
Molecular probes and sections were stained for 4 h (1:1000 in 1%
horse serum in TBST). Sections were stained with DAPI (1 mg/ml
in PBS) for 20 minutes and mounted on glass slides. Prolong Gold
anti-fade reagent (Invitrogen) was used to attach coverslips. A Zeiss
Axioplan 2 microscope was used to visualize IHC staining.
Flow Cytometry
To isolate tumor infiltrating immune cells, mice were perfused
with 100 ml heparinized Tyrode’s Solution 7 days after intratu-
moral injection of virus or saline. Brains were separated from the
meninges and removed from the skull. The tumor was carefully
dissected and removed, taking care to avoid the ventricles. The
tumor tissue was then diced with a razor blade before
homogenizing in RPMI medium using a glass Tenbroeck
homogenizer. Mononuclear cells were purified from brain tissue
by centrifugation (600xg) through a Percol gradient; mononuclear
cells migrate to the interface between 30% and 70% Percol. Cells
were counted and labeled with antibodies for analysis by flow
cytometry. Splenocytes were harvested and removed of red blood
cells using ACK solution (0.15 mM NH4Cl, 10 mM KHCO3, and
0.1 mM disodium EDTA at pH 7.2). Lymph nodes were
homogenized in a Tenbroeck homogenizer. Immune cells were
labeled with antibodies in cell surface staining buffer (0.1M PBS,
w/o Ca
++,M g
++, with 1% FBS, 0.1% Sodium Azide) for analysis
by flow cytometry using a FACScan flow cytometer (Beckton
Dickenson). To analyze Foxp3+ Tregs (CD3
+ CD4
+ Foxp3
+), we
stained with CD3-PE, CD4-PerCP and Foxp3-FITC. CD25
+ T
cells were stained with CD3-PE, CD4-PerCP, CD25-Biotin and
streptavidin-FITC (BD-Pharmingen). mDC (CD11c
+ MHC II
+
CD45
+) were stained with CD11c-PE, MHC II-FITC and CD45-
PerCP. Macrophages (CD11b
+ MHC II
+ CD45
+) were stained
with CD11c-PE, MHC II-FITC and CD45-PerCP. CD4
+ and
CD8a
+ T lymphocytes were stained with CD3-PE, CD4-PerCP
and CD8a-FITC. Other immune cells analyzed during this study
(not shown) were NK cells (CD3
2 CD161
+ CD45
+), NK-T cells
(CD3
+ CD161
+ CD45
+), and B lymphocytes (CD3
2 CD19
+
CD45
+). Analysis was performed using between 5 and 10 mice per
group. All percentages were calculated based on the total number
of CD45
+ immune cells in the tumor. For example, to calculate the
percentage of mDC in the tumor, the total number of gated mDC
(CD11c
+ MHCII
+ CD45
+) were counted and the percentage of
mDC in the tumor was determined by dividing the total number of
mDC by the total number of CD45
+ cells in the tumor. In Fig. 1 E
to mice 24 days after tumor implantation (7 days after treatment with Ad-Flt3L and Ad-TK) significantly reduced long term survival. (C) Tumor bearing
mice were treated with Ad-Flt3L and Ad-TK alone (black lines) or with Ad-Flt3L and Ad-TK with PC61 depletion on day 15 (green lines). Long term
survivors (60 d after tumor implantation) were assessed for a DTH response to irradiated GL26 cells injected into the right footpad (compared to PBS
only in the left footpad). Two Way ANOVA with Tukey’s post test was used to calculate significant differences between groups (***p,0.001 mice
treated with Ad-Flt3L and Ad-TK no depletion,ˆ ˆp,0.01 Ad-Flt3L and Ad-TK treated mice depleted with PC61 on day 15). (D) IFNc ELISPOT showing
the total number of IFNc producing T lymphocytes that were stimulated with DC loaded with GL26 tumor extracts. T lymphocytes were purified from
mice 10 d after treatment with either Ad-Flt3L and Ad-TK (+) or saline (2) as indicated. Black bars are T lymphocytes from mice that did not receive
CD25 depleting immunoglobulins. Green bars are T lymphocytes purified from mice depleted with PC61 2 days before treatment with Ad-Flt3L and
Ad-TK (day 15 after tumor implantation) and red bars are T lymphocytes purified from mice depleted with PC61 7 days after treatment with Ad-Flt3l
and Ad-TK (day 24 after tumor implantation). (E–G) Tregs (CD3e
+ CD4
+ Foxp3
+) infiltrating tumors (E), draining lymph nodes (F) or spleens (G) were
quantified in mice administered rat IgG1 isotype control (Iso) or PC61 on day 15 (15) or day 24 (24) as indicated in the graphs (left). Administration of
PC61 to mice resulted in long term depletion of Tregs in peripheral sites (spleen and lymph nodes) and at the tumor. Dot plots (right) display
representative means6SEM of Foxp3
+ Tregs quantified from 5 mice per group. The total number of T regs in the tumors (E) and the percentages of T
regs with respect to the total number of CD45+ cells in the draining lymph nodes (dLN) or spleen (F and G) are indicated in representative dot plots.
Two Way ANOVA with Tukey’s post test were used to determine significant differences (***p,0.001).
doi:10.1371/journal.pone.0001983.g006
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number of T cells (number of CD25+CD4+ cells/number of
CD3e+ cells).
Annexin V vs Propidium Iodide staining
Annexin V-FITC and propidium iodide were used to detect
apoptosis by flow cytometry as described previously [50]. Briefly
cells were growin in 96 well plates (20,000 cells per well) and
incubated with 100 mg/ml PC61 or 100 mg/ml rat IgG1 isotype
control for 48 h. Cells were then harvested gently using Trypsin
and resuspended in 100 ml Annexin V Binding Buffer (150mM
NaCl, 18mM CaCl2, 10mM HEPES, 5mM KCl, 1mM MgCl2).
Cells were incubated at room temperature (21 uC) for 5 minutes in
the dark, before adding propidium iodide (5 mg/ml) for 1 minute.
Cells were analyzed on a FACScan flow cytometer (BD
Biosciences). Cell Quest software (BD Biosciences) was used to
analyze the data.
BrdU labeling and detection
GL26 cell proliferation was assessed using a BrdU colorimetric
ELISA (ExAlpha Biologicals, Inc.). Briefly, GL26 cells were
incubated in 96 well plates at 20,000 cells per well. 100 mg/ml
PC61 or the rat IgG1 isotype control were added to wells and cells
were incubated for 24 h. 1x BrdU was added to the wells for 4 h
and BrdU incorporation into newly synthesized DNA strands was
detected exactly as recommended by the manufacturer.
ELISPOT
10
5 splenocytes from tumor bearing mice (wild type C57BL/6
or TLR2
2/2) treated with saline or Ad-Flt3L and Ad-TK were
prestimulated on a monolayer of GL26 cells (fixed in 1% PFA for
15 min at RT) in the presence of 10 U/ml IL-2 for 14 days. Fresh
IL-2 was added every 4
th day. BMDC (CD11c+, CD45+, MHC II
+) were cultured as described previously[51]. Briefly, bone marrow
was flushed out from the long bones of mice using 0.5 ml RPMI
media. A single cell suspension was created by pipetting up and
down with a P1000 pipette. BMDC were cultured from
hematopoietic stem cell precursors by supplementing the media
with 10 ng/ml Flt3L conditioned media. Fresh GMCSF and IL4
(10ng/ml each) was added every 2–3 days. By day 7, .90% of
loosely adherent cells were CD11c
+ (data not shown). Loosely
adherent cells were removed and were loaded with 100 mg/ml
Figure 7. PC61 inhibits T cell clonal expansion in the tumors in response to treatment with Ad-Flt3L and Ad-TK. (A) Administration of
PC61 to mice resulted in depletion of CD25
+ T lymphocytes in the spleen compared with administration of isotype controls. (B) C57BL/6 mice were
challenged with tumor cells on day 0, and treated on day 17 by intratumoral delivery of Ad-Flt3L and Ad-TK. Tregs were depleted on either day 15 or
day 24 by ip injection of PC61. Immune cells were isolated from the spleen, the cervical LN, and the tumor at day 27 post-tumor implantation to
determine the percentage of CD4
+ and CD8a
+ T cells in each tissue. (C–E) Total numbers of tumor infiltrating immune cells (CD45
+)( C), CD4
+ T cells
(CD3e
+ CD4
+ CD8a
2)( D) and CD8a
+ T cells (CD3e
+ CD4
2 CD8a
+)( E) and the percentage of CD4
+ T cells (F) and CD8a
+ T cells (G) in the draining lymph
nodes of mice were determined. Panels on the right hand side (C–G) display representative dot plots for immune cells purified from tumor bearing
mice treated with isotype rat IgG1 (day 15), PC61 (day 15) or PC61 (day 24) as indicated. The total number of CD45+ , CD4+ and CD8+ cells in the
tumors are shown in representative dot plots (C–E). The percentages of CD4+ and CD8+ T cells with respect to the total number of CD45+ cells in the
draining lymph nodes (dLN) are shown in representative dot plots (F and G). Two Way ANOVA with Tukey’s post test was used to analyze differences
between groups (C) and a two tailed t test was used to determine differences between saline and Ad-Flt3l/Ad-TK treated groups (D–G).
doi:10.1371/journal.pone.0001983.g007
Figure 8. CD4+ and CD8a+ T cells do not change in the spleen either after PC61 depletion or in response to treatment with Ad-Flt3L
and Ad-TK. Immune cells in the spleen were analyzed after tumor bearing C57BL/6 mice were treated with saline (white bars) or Ad-Flt3L and Ad-TK
(black bars) and administered rat IgG1 isotype control immunoglobulins (-) on day 15 or PC61 on day 15 or day 24. Macrophages (A) CD4+ T cells (B)
and CD8a+ T cells were assessed at day 27 post-tumor implantation using flow cytometry. Dot plots display CD8a against CD4 and are representative
of between 5 and 10 mice per group. The percentages of CD4+ and CD8+ T cells with respect to the total number of CD45+ cells in the spleen are
indicated in representative dot plots. Two Way ANOVA with Tukey’s post test was used to determine statistical significance.
doi:10.1371/journal.pone.0001983.g008
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PLoS ONE | www.plosone.org 14 April 2008 | Volume 3 | Issue 4 | e1983Figure 9. Antigen presenting cells increase in Tumor dLN and spleen after depletion with PC61 or in response to Ad-Flt3L and Ad-
TK. GL26 cells were implanted in the striatum of C57BL/6 mice. Rat IgG1 isotype control immunoglobulins (-) were administered on day 15 and PC61
was administered on day 15 or day 24 as indicated. Mice were treated with intratumoral injection of Ad-Flt3L and Ad-TK (black bars) or saline (white
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uC before washing 3 times with PBS. 1610
5 stimulator cells
(BMDC loaded with GL26 or LLc1 cell extract) were incubated
with 1610
5 responder cells (prestimulated T cells) in triplicate for
48 h on precoated 96 well mouse IFNc ELISPOT plates. IFNc
spots were developed as recommended by the manufacturer’s
detailed instructions (R&D Systems). ConA (1ug/ml, 4 h)
stimulation of WT and TLR2-/- splenocytes was used as a control.
Delayed Type Hypersensitivity (DTH) Test
DTH test was performed on long-term survivor mice 60 d after
tumor implantation as follows. 50,000 irradiated GL26 cells (30
Gy using a
137Cs source) were injected in 100 ml PBS in the right
rear footpad (right) or 100 ml PBS control in the left rear footpad
(left) of mice. The thickness of the footpad (left and right) was
recorded 0 h (immediately prior to depositing cells in the footpad),
4 h, 24 h and 48 h after injection of irradiated cells or PBS using a
vernier microcalipers.
Statistical Analysis
Kaplain-Meier survival curves were analyzed using the logrank
test (GraphPad Prism Version 3.03). One- or Two-way ANOVA
followed by Tukey’s test or unpaired two-tailed Student’s t test
were used to analyze all other data as indicated in the results and
the figure legends (NCSS software; NCSS, Kaysville, UT). When
data failed normality test or Levene equal-variance test, they were
square-root transformed. Results were expressed as the mean6-
SEM. A p value ,0.05 was considered the cut off for significance.
All experiments were performed at least twice.
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